Literature DB >> 1901780

Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG.

J Ma1, G V Chapman, S L Chen, G Melick, R Penny, S N Breit.   

Abstract

Antibody penetration of viable cells and interaction with intracellular antigens may have major consequences for immunopathological processes in connective tissue diseases. We have reported previously that antibody can penetrate viable human lymphocytes. To assess further the role of antinuclear antibodies in this process, peripheral blood lymphocytes (PBMC) were incubated with FITC-conjugated IgG fractions from sera containing anti-RNP (anti-RNP IgG), Ro(SS-A), La(SS-B) and dsDNA antibodies and control sera for 24 h. Using crystal violet to quench cell surface staining, intracellular fluorescence of viable lymphocytes was quantified on the flow cytometer. It was noted that anti-RNP IgG entered 46.4 +/- 7.2% of lymphocytes which was significantly higher than anti-Ro(SS-A) (29.9 +/- 4.1%, P less than 0.05), La(SS-B) (22.0 +/- 7.5%, P less than 0.01) IgG and control IgG (28.8 +/- 2.1%, P less than 0.05) and not statistically different from anti-dsDNA IgG (32.6 +/- 14.3%). Inhibition experiments showed that the increased number of cells penetrated by anti-RNP IgG was a specific process. Time-course studies showed that anti-RNP IgG entry into cells was different from pooled control IgG. With anti-RNP IgG, positive-staining lymphocytes gradually increased in number from 12 to 24 h incubation, whilst with pooled control IgG, the peak was reached within 5 min. Dual staining experiments suggested that whereas both anti-RNP IgG and pooled control IgG entered B and NK cells, anti-RNP IgG also entered T cells. Using IgG F(ab')2 and Fc fragments from either anti-RNP IgG or pooled control IgG to compete with their FITC-conjugated counterparts indicated that the entry of anti-RNP IgG into-viable cells appeared to involve both F(ab')2 and Fc fragments, and pooled control IgG depended exclusively on the Fc portion of IgG. Further investigation by incubating anti-RNP IgG with 35S-methionine-labelled monocyte-depleted PBMC (MD-PBMC) suggested that anti-RNP IgG might react with the corresponding antigens either on the cell surface or within the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901780      PMCID: PMC1535365          DOI: 10.1111/j.1365-2249.1991.tb08128.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Psoriasis and Raynaud's phenomenon associated with autoantibodies to U1 and U2 small nuclear ribonucleoproteins.

Authors:  W H Reeves; D E Fisher; R Wisniewolski; A B Gottlieb; N Chiorazzi
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

2.  In vitro study of the binding of antiribonucleoprotein antibodies to the nucleus of isolated living keratinocytes.

Authors:  L Galoppin; J H Saurat
Journal:  J Invest Dermatol       Date:  1981-04       Impact factor: 8.551

3.  Flow cytometry with crystal violet to detect intracytoplasmic fluorescence in viable human lymphocytes. Demonstration of antibody entering living cells.

Authors:  J A Ma; G V Chapman; S L Chen; R Penny; S N Breit
Journal:  J Immunol Methods       Date:  1987-11-23       Impact factor: 2.303

4.  Anti-RNP monoclonal antibodies derived from a mouse strain with lupus-like autoimmunity.

Authors:  P B Billings; R W Allen; F C Jensen; S O Hoch
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

5.  Purified lupus antigen La recognizes an oligouridylate stretch common to the 3' termini of RNA polymerase III transcripts.

Authors:  J E Stefano
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

6.  Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus.

Authors:  E M Tan; H G Kunkel
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

7.  Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies.

Authors:  V M Holers; B L Kotzin
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

8.  Monoclonal murine anti-DNA antibody interacts with living mononuclear cells.

Authors:  K Okudaira; H Yoshizawa; R C Williams
Journal:  Arthritis Rheum       Date:  1987-06

9.  Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes.

Authors:  W P LeFeber; D A Norris; S R Ryan; J C Huff; L A Lee; M Kubo; S T Boyce; B L Kotzin; W L Weston
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

10.  The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs.

Authors:  S L Wolin; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more
  10 in total

Review 1.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

2.  Passive transfer of antibodies to the linear epitope 60 kD Ro 273-289 induces features of Sjögren's syndrome in naive mice.

Authors:  J S Maier-Moore; B T Kurien; A D'Souza; L Bockus; S Asfa; Y Dorri; S Hubbell; O Yeliosof; D Obeso; T R Schoeb; R Jonsson; R H Scofield
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

3.  Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules.

Authors:  A Avrameas; T Ternynck; F Nato; G Buttin; S Avrameas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein.

Authors:  M Okawa-Takatsuji; S Aotsuka; M Fujinami; S Uwatoko; M Kinoshita; M Sumiya
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

5.  Antibody penetration of viable human cells. II. Anti-RNP antibodies binding to RNP antigen expressed on cell surface, which may mediate the antibody internalization.

Authors:  J Ma; N King; S L Chen; R Penny; S N Breit
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

6.  Enhanced synthesis of cytokines by peripheral blood monocytes cultured in the presence of autoantibodies against U1-ribonucleoprotein and/or negatively charged molecules: implication in the pathogenesis of pulmonary hypertension in mixed connective tissue disease (MCTD).

Authors:  M Okawa-Takatsuji; S Aotsuka; S Uwatoko; M Sumiya; R Yokohari
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

7.  A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen.

Authors:  Dahai Xue; Hong Shi; James D Smith; Xinguo Chen; Dennis A Noe; Tommy Cedervall; Derek D Yang; Elizabeth Eynon; Douglas E Brash; Michael Kashgarian; Richard A Flavell; Sandra L Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-03       Impact factor: 11.205

8.  A murine cytomegalovirus-neutralizing monoclonal antibody exhibits autoreactivity and induces tissue damage in vivo.

Authors:  A J Chapman; H E Farrell; J A Thomas; J M Papadimitriou; M J Garlepp; A A Scalzo; G R Shellam
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

9.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

Authors:  Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2013-01-09       Impact factor: 6.150

10.  Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin.

Authors:  Aggeliki D Sali; Ioannis Karakasiliotis; Maria Evangelidou; Stratis Avrameas; Peggy Lymberi
Journal:  Clin Transl Immunology       Date:  2015-10-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.